Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-22 15:36 CEST (UTC+2h)
balakotu
Regular

India,
2018-05-21 13:31

Posting: # 18792
Views: 463
 

 Replicate Study design for Brazil [Regulatives / Guidelines]

Dear All,

Brazil submission: Thus any body have any idea on Acceptance off Bio equivalence studies conducted in Replicate study design by ANVISA (Brazil). If acceptable what is the acceptance criteria to be followed (USFDA/Europe Approach).

Regards
Kotu


Edit: No need to post identical text twice within three days. The other post deleted (see the Forum’s Policy). [Helmut]
Helmut
Hero
avatar
Homepage
Vienna, Austria,
2018-05-21 16:47

@ balakotu
Posting: # 18794
Views: 384
 

 ABEL acc. to WHO

Hi Kotu,

» […] Acceptance off Bio equivalence studies conducted in Replicate study design by ANVISA (Brazil).

Replicate designs – although for average bioequivalence – are acceptable for the ANVISA for ages (even mentioned in the guidance).

» […] what is the acceptance criteria to be followed (USFDA/Europe Approach).

If you mean reference-scaling, the latter (actually the WHO’s). See this post. Confirmed by a Brazilian colleague earlier this month.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
weidson
Junior

Brazil,
2018-05-22 20:51

@ balakotu
Posting: # 18799
Views: 329
 

 Replicate Study design for Brazil

Dear balakotu

The ANVISA have adopted the EMA's Approach. However, for you use this approach you need to convince them that their drug is highly variable. I hope I have helped you.


Best Regards
Weidson C. de Souza


Edit: Post moved. [Helmut]
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,418 posts in 3,912 threads, 1,173 registered users;
online 27 (1 registered, 26 guests [including 7 identified bots]).

The greatest shortcoming of the human race is our inability
to understand the exponential function.    Albert Bartlett

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed